🧪
hypothesis

PINK1/Parkin mitophagy failure across PD, AD, and ALS

Hypothesis

PINK1/Parkin mitophagy failure across PD, AD, and ALS

Shared mechanism across PD, AD, ALS: Mitochondrial damage normally recruits PINK1/Parkin quality control; failure of this pathway increases mtDNA leakage, oxidative stress, and aggregate toxicity.
🧬 PINK1;PARK2🩺 multi🎯 Composite 80%💱 $0.53▲2.5%active
neurodegeneration
EvidenceStrong (88%)📖 25 cit🗣 1 debates 9 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.84 (15%) Evidence 0.78 (15%) Novelty 0.82 (12%) Feasibility 0.68 (12%) Impact 0.86 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.796 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite80%

🧪 Overview

Shared mechanism across PD, AD, ALS: Mitochondrial damage normally recruits PINK1/Parkin quality control; failure of this pathway increases mtDNA leakage, oxidative stress, and aggregate toxicity. PD is genetically anchored in the pathway, AD models improve when mitophagy is restored, and ALS models show PINK1/Parkin-dependent rescue of proteotoxic stress.

Falsifiable prediction: Enhancing PINK1/Parkin-dependent mitophagy should lower mitochondrial ROS and aggregate burden by at least 20% in PD dopaminergic, AD amyloid/tau, and ALS motor-neuron models, but the effect should disappear after PARK2 knockout.

Proposed experiment: Run parallel iPSC neuron assays with PINK1/Parkin activator, PARK2 knockout, and rescue arms; quantify mitophagy reporters, mtDNA-cGAS-STING activation, ROS, alpha-synuclein/tau/TDP-43 aggregate burden, and cell survival.

Cross-disease confidence rationale: Pathway is causal in PD and experimentally rescuable in AD/ALS models.

Internal SciDEX support: SciDEX support query found 61 matching hypotheses across 6 disease labels, including 61 with debate_count > 0.

...

🧬 Mechanism

🔗 Mechanism from KG for PINK1;PARK2

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    GBA1_mutations["GBA1 mutations"] -->|increases risk| PD["PD"]
    TREM2_R47H_variant["TREM2 R47H variant"] -->|increases risk| Ad["Ad"]
    alpha_synuclein_fibrils["alpha-synuclein fibrils"] -->|activates| NLRP3_Inflammasome["NLRP3 Inflammasome"]
    TFEB_overexpression["TFEB overexpression"] -.->|inhibits| tau_A__pathology["tau/Aβ pathology"]
    TARDBP_MUTATIONS["TARDBP MUTATIONS"] -->|causes| ALS_FTD["ALS/FTD"]
    TDP_43_INCLUSIONS["TDP-43 INCLUSIONS"] -->|associated with| ALS_FTD_1["ALS/FTD"]
    NfL_reduction["NfL reduction"] -->|biomarker for| als["als"]
    TARDBP["TARDBP"] -->|cross disease mech| ALS["ALS"]
    TARDBP_2["TARDBP"] -->|cross disease mech| FTD["FTD"]
    TARDBP_3["TARDBP"] -->|cross disease mech| AD_LATE["AD/LATE"]
    h_cross_synth_tdp43_rna_p["h-cross-synth-tdp43-rna-proteostasis"] -->|proposes shared me| TARDBP_4["TARDBP"]
    SNCA["SNCA"] -->|cross disease mech| PD_5["PD"]
    style GBA1_mutations fill:#ce93d8,stroke:#333,color:#000
    style PD fill:#ef5350,stroke:#333,color:#000
    style TREM2_R47H_variant fill:#ce93d8,stroke:#333,color:#000
    style Ad fill:#ef5350,stroke:#333,color:#000
    style alpha_synuclein_fibrils fill:#4fc3f7,stroke:#333,color:#000
    style NLRP3_Inflammasome fill:#ce93d8,stroke:#333,color:#000
    style TFEB_overexpression fill:#4fc3f7,stroke:#333,color:#000
    style tau_A__pathology fill:#4fc3f7,stroke:#333,color:#000
    style TARDBP_MUTATIONS fill:#ce93d8,stroke:#333,color:#000
    style ALS_FTD fill:#ef5350,stroke:#333,color:#000
    style TDP_43_INCLUSIONS fill:#4fc3f7,stroke:#333,color:#000
    style ALS_FTD_1 fill:#ef5350,stroke:#333,color:#000
    style NfL_reduction fill:#ce93d8,stroke:#333,color:#000
    style als fill:#ef5350,stroke:#333,color:#000
    style TARDBP fill:#4fc3f7,stroke:#333,color:#000
    style ALS fill:#ef5350,stroke:#333,color:#000
    style TARDBP_2 fill:#4fc3f7,stroke:#333,color:#000
    style FTD fill:#ef5350,stroke:#333,color:#000
    style TARDBP_3 fill:#4fc3f7,stroke:#333,color:#000
    style AD_LATE fill:#ef5350,stroke:#333,color:#000
    style h_cross_synth_tdp43_rna_p fill:#4fc3f7,stroke:#333,color:#000
    style TARDBP_4 fill:#4fc3f7,stroke:#333,color:#000
    style SNCA fill:#4fc3f7,stroke:#333,color:#000
    style PD_5 fill:#ef5350,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix9 supports0 contradicts
Supports
PINK1, Parkin, and mitochondrial fidelity are central to Parkinson's disease.
2015PMID:25611507high
Supports
Mitophagy inhibits amyloid-beta and tau pathology in AD models.
2019PMID:30742114high
Supports
PINK1/PARKIN signaling links neurodegeneration and neuroinflammation.
2020PMID:33168089high
Supports
PINK1-Parkin-dependent mitophagy antagonizes ALS pathologies in models.
2025PMID:41094045medium
Supports
PINK1/Parkin-mediated mitophagy activation reduces mitochondrial ROS levels by selectively clearing damaged mitochondria in neurons
PMID:28711444
Supports
Impaired mitophagy causes accumulation of neurotoxic protein aggregates (α-synuclein, tau, TDP-43) through disruption of mitochondrial proteostasis
PMID:38185999
Supports
Mitochondrial depolarization stabilizes PINK1 on the outer membrane, which phosphorylates ubiquitin and Parkin, triggering ubiquitination of mitochondrial proteins and autophagosomal engulfment.
PMID:31432739
Supports
Enhancing PINK1/Parkin mitophagy in iPSC-derived neurons reduces mtDNA-cGAS-STING activation and lowers intracellular ROS levels by ≥20%.
PMID:35512628
Supports
Enhancing PINK1/Parkin mitophagy in iPSC-derived neurons reduces mtDNA-cGAS-STING activation and lowers intracellular ROS levels by ≥20%.
PMID:31583052
📖 Linked Papers (4)Export BibTeX ↗
Isoginkgetin antagonizes ALS pathologies in its animal and patient iPSC models via PINK1-Parkin-dependent mitophagy.
EMBO molecular medicine (2025) · PubMed:41094045 ↗
No figures
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.
Acta neuropathologica communications (2020) · PubMed:33168089 ↗
No figures
Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease.
Nature neuroscience (2019) · PubMed:30742114 ↗
No figures
The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease.
Neuron (2015) · PubMed:25611507 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — PINK1;PARK2

No curated PDB or AlphaFold mapping for PINK1;PARK2 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for PINK1;PARK2 →

No DepMap CRISPR Chronos data found for PINK1;PARK2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0004
Events (7d)
1
Price History
▲2.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
Enhancing PINK1/Parkin-dependent mitophagy should lower mitochondrial ROS and aggregate burden by at least 20% in PD dopaminergic, AD amyloid/tau, and ALS motor-neuron models, but the effect should diIf this mechanism is real, then Enhancing PINK1/Parkin-dependent mitophagy should lower mitochondrial ROS and aggregate burden by at least 20% in PD dopaminergi— no observation —pending0.78
🔮 Falsifiable Predictions (1)
pendingconf 78%
Enhancing PINK1/Parkin-dependent mitophagy should lower mitochondrial ROS and aggregate burden by at least 20% in PD dopaminergic, AD amyloid/tau, and ALS motor-neuron models, but the effect should disappear after PARK2 knockout.
Predicted outcome: If this mechanism is real, then Enhancing PINK1/Parkin-dependent mitophagy should lower mitochondrial ROS and aggregate burden by at least 20% in PD d
Falsification: Falsified if the experiment produces results more than 20% below the predicted effect size
View on SciDEX ↗